(Q33341208)

English

Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Y M Chen

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

R P Perng

2

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Y C Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

J F Shih

4

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

C S Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

C M Tsai

6

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

J Whang-Peng

7

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

108-115

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Paclitaxel-based therapy in non-small-cell lung cancer: improved third generation chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF009

21 January 2018

Identifiers

10.1093/ANNONC/MDF009

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

release_fmalhcubgnenpiu7t3p6wqcshu

1 reference

https://api.fatcat.wiki/v0/release/fmalhcubgnenpiu7t3p6wqcshu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33341208&oldid=1966787617"